• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial

Malmström, Annika; Poulsen, Hans Skovgaard; Grønberg, Bjørn Henning; Stragliotto, Giuseppe; Hansen, Steinbjørn; Asklund, Thomas; Holmlund, Birgitta; Lysiak, Malgorzata; Dowsett, Joseph; Kristensen, Bjarne Winther; Söderkvist, Peter; Rosell, Johan; Henriksson, Roger
Journal article, Peer reviewed
Submitted version
Thumbnail
View/Open
Figures+20170328.docx (143.2Kb)
Acta+Oncologica+manuskript+20170512+-+cleen.docx (87.59Kb)
Tables+20170328.docx (38.66Kb)
URI
http://hdl.handle.net/11250/2582951
Date
2017
Metadata
Show full item record
Collections
  • Institutt for klinisk og molekylær medisin [2067]
  • Publikasjoner fra CRIStin - NTNU [20842]
Original version
Acta Oncologica. 2017, 56 (12), 1776-1785.   10.1080/0284186X.2017.1332780
Abstract
Introduction: A pilot study of temozolomide (TMZ) given before radiotherapy (RT) for anaplastic astrocytoma (AA) and glioblastoma (GBM) resulted in prolonged survival compared to historical controls receiving RT alone. We therefore investigated neoadjuvant TMZ (NeoTMZ) in a randomized trial. During enrolment concomitant and adjuvant radio-chemotherapy with TMZ became standard treatment. The trial was amended to include concurrent TMZ.

Patients and Methods: Patients, after surgery for GBM or AA, age ≤ 60 years and performance status (PS) 0-2, were randomized to either 2-3 cycles of TMZ, 200 mg/m2 days 1-5 every 28 days, followed by RT 60 Gy in 30 fractions or RT only. Patients without progressive disease after 2 TMZ cycles, received the 3rd cycle. From March 2005 TMZ 75 mg/m2 was administered daily concomitant with RT. TMZ was recommended first line treatment at progression. Primary endpoint was overall survival and secondary safety.

Results: The study closed prematurely after enrolling 144 patients, 103 with GBM and 41 with AA. Median age was 53 years (range 24-60) and 89 (62%) were male. PS was 0-1 for 133 (92%) patients, 53 (37%) had complete surgical resection and 18 (12%) biopsy. Ninety-two (64%) received TMZ concomitant with RT. Seventy-two (50%) were randomized to neoadjuvant treatment. For the whole study population survival was 20.3 months for RT and 17.7 months for NeoTMZ (p=0.76), this not reaching the primary objective. For the preplanned subgroup analysis we found that NeoTMZ AA patients had a median survival of 95.1 months compared to 35.2 months for RT (p=0.022). For patients with GBM, no difference in survival was observed (p=0.10). MGMT and IDH status affected outcome.

Conclusion: No advantage of NeoTMZ was noted for the whole study population or subgroup of GBM, while NeoTMZ resulted in 5 years longer median survival for patients diagnosed as AA.
Publisher
Taylor & Francis
Journal
Acta Oncologica

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit